My Queue

There are no Videos in your queue.

Click on the Add to next to any video to save to your queue.

There are no Articles in your queue.

Click on the Add to next to any article to save to your queue.

There are no Podcasts in your queue.

Click on the Add to next to any podcast episode to save to your queue.

You're not following any authors.

Click the Follow button on any author page to keep up with the latest content from your favorite authors.

Medical Marijuana

DEA Moves Some CBD Medicines off Schedule 1

Though a limited expansion of cannabis access it is a significant time DEA has removed cannabis in any from Schedule 1.
DEA Moves Some CBD Medicines off Schedule 1
Image credit: Bloomberg Creative Photos | Getty Images
2 min read
Brought to you by Marijuana Business Daily

(This is an abridged version of a story that appears at HempIndustryDaily.com.)

The U.S. Drug Enforcement Administration has taken some cannabidiol out of the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.

It’s a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.

The DEA announced Thursday that drugs including CBD with THC content below 0.1% are now considered Schedule 5 drugs, as long as they have been approved by the U.S. Food and Drug Administration.

It is the first time the agency has lowered any type of cannabis from Schedule 1.

The action came three months after the FDA approved its first nonsynthetic, cannabis-derived medicine, a CBD preparation for rare types of epilepsy. The drug, Epidiolex, is made from cannabis grown in Europe.

The DEA announcement means Epidiolex will be distributed through traditional pharmaceutical channels, from a doctor’s prescription to a drug store, instead of through a medical marijuana dispensary or designated MMJ caregiver.

Marijuana businesses cheered the DEA change as a signal that opposition to cannabis is starting to crumble.

“We’re one step closer to finally ending prohibition and legitimizing the industry,” said James Minutello, CEO of Leaf Logix, a Glendale, California, company that makes business management software for the cannabis industry.

This article appeared first in Marijuana Business Daily.

Latest on Green Entrepreneur